S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

KarXT Improves Alzheimer’s Psychosis Scores in Phase 3 Study

Bristol Myers Squibb said preliminary Phase 3 results show its KarXT treatment improved scores for hallucinations and delusions, as well as overall disease severity, in patients with Alzheimer’s disease. The company released the findings Wednesday while awaiting the study’s full results.

KarXT Improves Alzheimer’s Psychosis Scores in Phase 3 Study

Separate findings on long-term safety and tolerability showed KarXT was generally well tolerated through week 52, with low rates of discontinuation, according to the company. Treatment-emergent adverse events occurred in 65% of participants; serious treatment-emergent adverse events were reported in 7.7%.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!